Hunan Jingfeng Pharmaceutical
Hunan Jingfeng Pharmaceutical Co.,Ltd. manufactures and sells chemical drugs and biological agents in China. The company's principal product is sodium hyaluronate injection for use in orthopedics and surgery applications. It also offers ophthalmic equipment and API products, as well as engages in the research and development of antitumor, cancer, and cardiovascular drugs; and distributed in the f… Read more
Market Cap & Net Worth: Hunan Jingfeng Pharmaceutical (000908)
Hunan Jingfeng Pharmaceutical (SHE:000908) has a market capitalization of $605.52 Million (CN¥4.44 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #14971 globally and #3992 in its home market, demonstrating a -12.78% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Jingfeng Pharmaceutical's stock price CN¥5.05 by its total outstanding shares 879774351 (879.77 Million).
Hunan Jingfeng Pharmaceutical Market Cap History: 2015 to 2026
Hunan Jingfeng Pharmaceutical's market capitalization history from 2015 to 2026. Data shows change from $1.74 Billion to $605.52 Million (-8.86% CAGR).
Hunan Jingfeng Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Jingfeng Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.41x
Hunan Jingfeng Pharmaceutical's market cap is 1.41 times its annual revenue
0.84x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
3.85x
Hunan Jingfeng Pharmaceutical's market cap is 3.85 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.74 Billion | $2.46 Billion | $324.10 Million | 0.71x | 5.37x |
| 2016 | $1.25 Billion | $2.64 Billion | $340.03 Million | 0.47x | 3.68x |
| 2017 | $725.99 Million | $2.58 Billion | $162.09 Million | 0.28x | 4.48x |
| 2018 | $532.38 Million | $2.59 Billion | $186.81 Million | 0.21x | 2.85x |
| 2019 | $454.44 Million | $1.34 Billion | -$921.55 Million | 0.34x | N/A |
| 2020 | $544.37 Million | $877.92 Million | -$1.16 Billion | 0.62x | N/A |
| 2021 | $522.79 Million | $811.18 Million | -$201.64 Million | 0.64x | N/A |
| 2022 | $381.30 Million | $840.66 Million | -$100.89 Million | 0.45x | N/A |
| 2023 | $388.49 Million | $656.89 Million | -$215.14 Million | 0.59x | N/A |
| 2024 | $586.34 Million | $416.03 Million | $152.30 Million | 1.41x | 3.85x |
Competitor Companies of 000908 by Market Capitalization
Companies near Hunan Jingfeng Pharmaceutical in the global market cap rankings as of March 18, 2026.
Key companies related to Hunan Jingfeng Pharmaceutical by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Hunan Jingfeng Pharmaceutical Historical Marketcap From 2015 to 2026
Between 2015 and today, Hunan Jingfeng Pharmaceutical's market cap moved from $1.74 Billion to $ 605.52 Million, with a yearly change of -8.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥605.52 Million | -29.76% |
| 2025 | CN¥862.12 Million | +47.03% |
| 2024 | CN¥586.34 Million | +50.93% |
| 2023 | CN¥388.49 Million | +1.89% |
| 2022 | CN¥381.30 Million | -27.06% |
| 2021 | CN¥522.79 Million | -3.96% |
| 2020 | CN¥544.37 Million | +19.79% |
| 2019 | CN¥454.44 Million | -14.64% |
| 2018 | CN¥532.38 Million | -26.67% |
| 2017 | CN¥725.99 Million | -41.91% |
| 2016 | CN¥1.25 Billion | -28.15% |
| 2015 | CN¥1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Hunan Jingfeng Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $605.52 Million USD |
| MoneyControl | $605.52 Million USD |
| MarketWatch | $605.52 Million USD |
| marketcap.company | $605.52 Million USD |
| Reuters | $605.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.